Bard Announces Issuance Of ePTFE Vascular Patent.Business Editors/Health Writers MURRAY HILL, N.J.--(BUSINESS WIRE)--Aug. 20, 2002 C. R. Bard C. R. Bard, Inc. (NYSE: BCR) is one of the large S&P 500 companies of the United States, a surgical specialties and hospital medical device manufacturer in Murray Hill, New Jersey. It is named after its founder, who sold the company within only a few years of its founding. , Inc. (NYSE NYSE See: New York Stock Exchange :BCR BCR B Cell Receptor BCR Business Communications Review (magazine) BCR Banca Comerciala Romana (Romanian bank) BCR Breakpoint Cluster Region BCR Benefit/Cost Ratio BCR Bay City Rollers ) announced that the U.S. Patent Office today issued a patent to Dr. David Goldfarb for ePTFE (expanded polytetrafluoroethylene) vascular applications. Dr. Goldfarb has licensed his rights exclusively to Bard's wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. , IMPRA, Inc. ePTFE is used in vascular prosthetic applications, including grafts, which are devices that are commonly used to surgically bypass diseased arteries or to provide blood access for hemodialysis. In addition, ePTFE can be used to cover stents for peripheral and coronary applications and in endovascular devices to treat abdominal aortic aneurysms. It is readily accepted by body tissue, pliable and easily sutured. It has an excellent history as an implant material in many applications. William H. Longfield, Bard's chairman and chief executive officer, stated, "The issuance of this patent provides Bard with broad and pre-eminent intellectual property rights to ePTFE technology. We believe that the establishment of these rights represents the successful completion of a critical step in our strategy of leadership in the peripheral vascular market." The way for the patent issuance was cleared last year when, after a series of judicial and administrative rulings upholding Dr. Goldfarb's position, the U.S. Court of Appeals for the Federal Circuit affirmed the decision of the Board of Patent Appeals and Interferences The Board of Patent Appeals and Interferences (BPAI) is a body of the United States Patent and Trademark Office (USPTO), which decides issues of patentability. If an applicant for an invention cannot convince a patent examiner that they are entitled to their claims, then the of the United States Patent and Trademark Office The United States Patent and Trademark Office (PTO or USPTO) is an agency in the United States Department of Commerce that provides patent protection to inventors and businesses for their inventions, and trademark registration for product and intellectual property that awarded priority of inventorship to Dr. Goldfarb. C. R. Bard, Inc., (www.crbard.com) headquartered in Murray Hill, New Jersey
This press release contains forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. Please refer to our June 30, 2002, Form 10-Q for a statement with regard to forward-looking statements, including disclosure of the factors that could cause actual results to differ materially from those expressed or implied. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion